Skip to contents

Model and source

  • Citation: Dumortier T, Valenzuela G, Churchill M, Mijatovic J, Bruin G, Pricop L, Richards H, Renard D, Singhal A, Marathe A. Model-Informed Drug Development-Based Bridging from Subcutaneous to Intravenous Secukinumab Dosing: Approval in Psoriatic Arthritis and Axial Spondyloarthritis. Clin Pharmacol Ther. 2025;118(2):480-488. doi:10.1002/cpt.3716.
  • Description: Two-compartment population PK model for secukinumab (anti-IL-17A IgG1) after subcutaneous and intravenous dosing in adults with psoriatic arthritis, ankylosing spondylitis or non-radiographic axial spondyloarthritis (Dumortier 2025; 14 phase II/III trials, 5270 patients). First-order SC absorption with ka fixed at 0.18/day and bioavailability 0.783; zero-order IV infusion into the central compartment; linear elimination. Baseline body weight (reference 84 kg) scales CL, Vc and Vp by power functions, and CL is 1.13-fold higher in Asian patients. Correlated IIV on CL and Vc, independent IIV on Vp, proportional residual error. Used to select the approved 1.75 mg/kg IV q4w regimen (with or without a 6 mg/kg IV loading dose).
  • Article: https://doi.org/10.1002/cpt.3716 (open access; PMC12272323)

Dumortier 2025 bridged subcutaneous (SC) secukinumab to an intravenous (IV) regimen for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). A population PK model, fitted to 14 phase II/III trials, identified 1.75 mg/kg IV every 4 weeks (q4w), with or without a 6 mg/kg IV loading dose, as the regimen whose steady-state exposure lies between the approved 150 mg and 300 mg SC q4w regimens. Landmark exposure-response models for efficacy, fitted to SC-only data at Weeks 16 and 52, then predicted the efficacy of the IV regimen.

The paper contributes 33 models to nlmixr2lib:

  • Dumortier_2025_secukinumab – the two-compartment population PK model (Supplementary Table S3 and the supplementary NONMEM control stream).
  • 32 logistic sigmoid-Emax exposure-efficacy models, one per endpoint and assessment week, named Dumortier_2025_secukinumab_<psa|as>_<w16|w52>_<endpoint>. Each has the form logit(p) = E0 + (Emax - E0) * Cmin^2 / (EC50^2 + Cmin^2) (Hill fixed at 2) with the pre-dose concentration supplied in the CTROUGH column (ug/mL).

The exposure-safety analysis (semi-parametric Cox models with a penalised spline of the 28-day running-average concentration) is not packaged: the baseline hazard is non-parametric and the spline coefficients are not reported, so there is no closed-form model to encode.

Population

The PK model was developed in 5270 patients from 14 trials (two phase II IV studies and the phase III MEASURE 1-5, FUTURE 1-5, PREVENT and INVIGORATE-2 studies; Table S1). Per Table 1, mean age was 45.1 years (SD 12.9), mean body weight 81.6 kg (SD 19.4), 55% were male, 80% White and 15% Asian; 58% had PsA, 31% ankylosing spondylitis (AS) and 10% non-radiographic axSpA. The model was externally validated on the 516 axSpA patients of INVIGORATE-1 (Figure S1).

The exposure-efficacy models were fitted to SC-treated patients only: at Week 52, 1595 PsA patients from FUTURE 1-5 and 934 AS patients from MEASURE 1-5; at Week 16, placebo and SC patients from FUTURE 2-5 (PsA) and MEASURE 2, 4 and 5 (AS), excluding arms with a 10 mg/kg IV loading regimen.

str(rxode2::rxode(readModelDb("Dumortier_2025_secukinumab"))$population)
#> ℹ parameter labels from comments will be replaced by 'label()'
#> List of 12
#>  $ species       : chr "human"
#>  $ n_subjects    : int 5270
#>  $ n_studies     : int 14
#>  $ n_observations: chr "24149 serum secukinumab concentrations (4396 after IV and 19753 after SC dosing)"
#>  $ age_range     : chr "mean 45.1 years (SD 12.9)"
#>  $ weight_range  : chr "mean 81.6 kg (SD 19.4)"
#>  $ sex_female_pct: num 45
#>  $ race_ethnicity: Named num [1:7] 80 15 3 1 1 0 0
#>   ..- attr(*, "names")= chr [1:7] "White" "Asian" "Other" "Black" ...
#>  $ disease_state : chr "Psoriatic arthritis (58%), ankylosing spondylitis (31%) and non-radiographic axial spondyloarthritis (10%)"
#>  $ dose_range    : chr "0.1, 1 or 10 mg/kg IV at weeks 0 and 3 (phase II); 75, 150 or 300 mg SC q4w with or without weekly SC loading o"| __truncated__
#>  $ regions       : chr "Multinational"
#>  $ notes         : chr "Model-development population of Dumortier 2025 Table 1 (n = 5270). INVIGORATE-1 (n = 516, axSpA) was held out f"| __truncated__

Source trace

Population PK model

Equation / parameter Value Source location
lcl (CL, 84 kg non-Asian) log(0.171) L/day Table S3
lvc (Vc, 84 kg) log(3.32) L Table S3
lq (Q) log(0.35) L/day Table S3
lvp (Vp, 84 kg) log(2.63) L Table S3
lka (KA) fixed(log(0.18)) 1/day Table S3 (‘0.18 (fixed)’); control stream (0.18 FIX)
lfdepot (F1) log(0.783) Table S3
e_wt_cl, e_wt_vc, e_wt_vp 0.892, 0.651, 0.712 Table S3 ‘CL/Vc/Vp ~weight’
e_race_asian_cl 1.13 Table S3 ‘CL ~Asian’
etalcl + etalvc c(0.0912, 0.0489, 0.0691) Table S3 omega2 CL, covariance, omega2 Vc
etalvp 0.113 Table S3 omega2 Vp
propSd sqrt(0.0544) Table S3 ‘delta2 prop’ (variance)
cl = CL * (WT/84)^e_wt_cl * e_race_asian_cl^RACE_ASIAN n/a control stream $PK (TVCL)
vc, vp power weight scaling; no weight effect on Q n/a control stream $PK (TVV2, TVV3, TVQ)
Two-compartment ODEs, SC depot, IV into central n/a control stream ADVAN4 TRANS4; Supplementary Methods
Cc = central / vc (mg/L = ug/mL) n/a control stream S2 = V2/1000

Exposure-efficacy models

Dumortier 2025 prints the equation (main text Methods and Supplementary Methods, Hill coefficient fixed at 2) but not E0, Emax or EC50 for any endpoint. The maintainers recovered them by pixel-digitising the fitted black curves in Figures S3 (PsA, Week 52), S4 (AS, Week 52), S6 (PsA, Week 16) and S7 (AS, Week 16) of the supplementary Word file and refitting the same equation by least squares. The panel axes were calibrated from the detected tick marks. The refits reproduce the drawn curves to within line width (RMSE 0.0003 to 0.0033 probability units over 168 to 238 traced points per panel), so they read back the authors’ fitted curves rather than re-estimating anything from data.

er_models <- tibble::tribble(
  ~disease, ~week, ~token, ~endpoint,
  "PsA", 52, "acr20", "ACR20",
  "PsA", 52, "acr50", "ACR50",
  "PsA", 52, "acr70", "ACR70",
  "PsA", 52, "haqdi", "HAQ-DI response",
  "PsA", 52, "mda", "MDA",
  "PsA", 52, "pasdaslda", "PASDAS LDA incl. remission",
  "PsA", 52, "pasi90", "PASI90",
  "PsA", 52, "dactylitis", "Resolution of dactylitis",
  "PsA", 52, "enthesitis", "Resolution of enthesitis",
  "AS", 52, "asas56", "ASAS 5/6",
  "AS", 52, "asaspr", "ASAS partial remission",
  "AS", 52, "asas20", "ASAS20",
  "AS", 52, "asas40", "ASAS40",
  "AS", 52, "asdasid", "ASDAS-CRP inactive disease",
  "AS", 52, "asdasmi", "ASDAS-CRP major improvement",
  "AS", 52, "basdai50", "BASDAI50"
)
er_models <- dplyr::bind_rows(er_models, dplyr::mutate(er_models, week = 16)) |>
  dplyr::mutate(
    model = sprintf("Dumortier_2025_secukinumab_%s_w%d_%s", tolower(disease), week, token),
    figure = dplyr::case_when(
      disease == "PsA" & week == 52 ~ "Figure S3",
      disease == "AS" & week == 52 ~ "Figure S4",
      disease == "PsA" & week == 16 ~ "Figure S6",
      TRUE ~ "Figure S7"
    )
  )
er_ui <- lapply(er_models$model, function(nm) rxode2::rxode(readModelDb(nm)))
names(er_ui) <- er_models$model
er_models$output <- vapply(er_ui, function(ui) ui$predDf$var, character(1))
er_models$E0 <- vapply(er_ui, function(ui) ui$theta[["e0"]], numeric(1))
er_models$Emax <- vapply(er_ui, function(ui) ui$theta[["emax"]], numeric(1))
er_models$EC50 <- vapply(er_ui, function(ui) exp(ui$theta[["lec50"]]), numeric(1))

er_models |>
  dplyr::select(disease, week, endpoint, figure, output, E0, Emax, EC50) |>
  dplyr::rename(
    "Disease" = disease, "Week" = week, "Endpoint" = endpoint,
    "Source panel" = figure, "Output" = output, "EC50 (ug/mL)" = EC50
  ) |>
  knitr::kable(digits = 3, caption = "Digitised exposure-efficacy parameters (logit scale; Hill fixed at 2).")
Digitised exposure-efficacy parameters (logit scale; Hill fixed at 2).
Disease Week Endpoint Source panel Output E0 Emax EC50 (ug/mL)
PsA 52 ACR20 Figure S3 prob_acr20 -0.414 1.060 5.27
PsA 52 ACR50 Figure S3 prob_acr50 -1.334 0.039 6.86
PsA 52 ACR70 Figure S3 prob_acr70 -14.683 -0.851 1.49
PsA 52 HAQ-DI response Figure S3 prob_haqdi_response 0.028 0.430 10.90
PsA 52 MDA Figure S3 prob_minimal_disease_activity -2.140 -0.313 7.77
PsA 52 PASDAS LDA incl. remission Figure S3 prob_pasdas_lda -2.262 0.494 7.70
PsA 52 PASI90 Figure S3 prob_pasi90 -1.432 0.956 12.20
PsA 52 Resolution of dactylitis Figure S3 prob_dactylitis_resolution 1.531 -27.659 400.00
PsA 52 Resolution of enthesitis Figure S3 prob_enthesitis_resolution -7.517 0.769 0.97
AS 52 ASAS 5/6 Figure S4 prob_asas56 -0.507 0.621 8.68
AS 52 ASAS partial remission Figure S4 prob_asas_partial_remission -5.818 -0.804 4.13
AS 52 ASAS20 Figure S4 prob_asas20 0.710 1.841 26.90
AS 52 ASAS40 Figure S4 prob_asas40 -0.497 0.715 12.50
AS 52 ASDAS-CRP inactive disease Figure S4 prob_asdas_inactive_disease -2.537 -0.322 14.40
AS 52 ASDAS-CRP major improvement Figure S4 prob_asdas_major_improvement -2.436 -0.098 7.97
AS 52 BASDAI50 Figure S4 prob_basdai50 -1.020 0.407 9.26
PsA 16 ACR20 Figure S6 prob_acr20 -1.058 0.493 9.00
PsA 16 ACR50 Figure S6 prob_acr50 -2.422 -0.425 9.24
PsA 16 ACR70 Figure S6 prob_acr70 -3.471 -1.381 9.12
PsA 16 HAQ-DI response Figure S6 prob_haqdi_response -0.529 0.227 6.22
PsA 16 MDA Figure S6 prob_minimal_disease_activity -2.694 -0.807 12.00
PsA 16 PASDAS LDA incl. remission Figure S6 prob_pasdas_lda -2.047 -0.090 13.00
PsA 16 PASI90 Figure S6 prob_pasi90 -2.576 0.599 15.00
PsA 16 Resolution of dactylitis Figure S6 prob_dactylitis_resolution -0.528 0.338 5.68
PsA 16 Resolution of enthesitis Figure S6 prob_enthesitis_resolution -0.757 0.178 13.30
AS 16 ASAS 5/6 Figure S7 prob_asas56 -1.340 0.157 9.82
AS 16 ASAS partial remission Figure S7 prob_asas_partial_remission -2.716 -1.527 7.05
AS 16 ASAS20 Figure S7 prob_asas20 -0.371 0.867 13.50
AS 16 ASAS40 Figure S7 prob_asas40 -1.320 0.058 12.60
AS 16 ASDAS-CRP inactive disease Figure S7 prob_asdas_inactive_disease -3.264 -1.232 13.20
AS 16 ASDAS-CRP major improvement Figure S7 prob_asdas_major_improvement -2.605 -0.490 10.30
AS 16 BASDAI50 Figure S7 prob_basdai50 -1.406 -0.112 14.70

Virtual cohort

Dumortier 2025 simulated non-Asian patients whose body weights were resampled from INVIGORATE-1 (axSpA) and INVIGORATE-2 (PsA). Individual weights are not public; INVIGORATE-1 reports a mean of 78 kg (SD 18.2, Table 1). The cohort below draws weight from a log-normal distribution with mean 79 kg and SD 19 kg, truncated to 40-170 kg, all non-Asian.

set.seed(3716)
rxode2::rxSetSeed(3716)
n_per_arm <- 200
draw_wt <- function(n, mean = 79, sd = 19) {
  s2 <- log(1 + (sd / mean)^2)
  pmin(pmax(rlnorm(n, log(mean) - s2 / 2, sqrt(s2)), 40), 170)
}

tinf <- 0.5 / 24 # 30-minute infusion, in days
dose_days <- seq(0, 336, by = 28)
regimens <- tibble::tribble(
  ~regimen, ~route, ~maint, ~load,
  "1.75 mg/kg IV q4w", "IV", 1.75, NA,
  "1.75 mg/kg IV q4w + 6 mg/kg IV load", "IV", 1.75, 6,
  "150 mg SC q4w", "SC", 150, NA,
  "150 mg SC q4w + weekly load", "SC", 150, 150,
  "300 mg SC q4w + weekly load", "SC", 300, 300
)

make_cohort <- function(reg, id_offset) {
  subj <- tibble::tibble(id = id_offset + seq_len(n_per_arm), WT = draw_wt(n_per_arm), RACE_ASIAN = 0L)
  doses <- if (reg$route == "IV") {
    amt_mgkg <- c(if (is.na(reg$load)) reg$maint else reg$load, rep(reg$maint, length(dose_days) - 1))
    tidyr::expand_grid(subj, tibble::tibble(time = dose_days, mgkg = amt_mgkg)) |>
      dplyr::mutate(amt = mgkg * WT, rate = amt / tinf, cmt = "central", mgkg = NULL)
  } else {
    # Weekly loading at Weeks 0, 1, 2, 3 and 4, then q4w (Table S4 header).
    t_sc <- if (is.na(reg$load)) dose_days else sort(unique(c(c(0, 7, 14, 21), dose_days)))
    tidyr::expand_grid(subj, tibble::tibble(time = t_sc)) |>
      dplyr::mutate(amt = reg$maint, rate = 0, cmt = "depot")
  }
  obs_t <- sort(unique(c(
    seq(0, 364, by = 1),
    dose_days[-1] - 1e-3, # pre-dose troughs
    dose_days + tinf # end of infusion
  )))
  obs <- tidyr::expand_grid(subj, time = obs_t) |>
    dplyr::mutate(amt = 0, rate = 0, cmt = "central")
  dplyr::bind_rows(
    dplyr::mutate(doses, evid = 1L),
    dplyr::mutate(obs, evid = 0L)
  ) |>
    dplyr::mutate(regimen = reg$regimen) |>
    dplyr::arrange(id, time, dplyr::desc(evid))
}

events <- dplyr::bind_rows(lapply(seq_len(nrow(regimens)), function(i) {
  make_cohort(regimens[i, ], id_offset = (i - 1L) * n_per_arm)
}))
stopifnot(!anyDuplicated(unique(events[, c("id", "time", "evid")])))

Simulation

mod <- readModelDb("Dumortier_2025_secukinumab")
sim <- rxode2::rxSolve(mod, events = events, keep = c("regimen", "WT"), returnType = "data.frame")
#> ℹ parameter labels from comments will be replaced by 'label()'

Replicate published figures

Figure 3 – median concentration-time profiles

sim |>
  dplyr::filter(regimen != "150 mg SC q4w + weekly load") |>
  dplyr::group_by(regimen, time) |>
  dplyr::summarise(Cc = median(Cc), .groups = "drop") |>
  ggplot(aes(time / 7, Cc, colour = regimen)) +
  geom_line() +
  labs(
    x = "Time (weeks)", y = "Secukinumab (ug/mL)", colour = NULL,
    title = "Median simulated secukinumab concentration",
    caption = "Replicates Figure 3 of Dumortier 2025."
  ) +
  theme(legend.position = "bottom") +
  guides(colour = guide_legend(ncol = 2))

Table S4 – median pre-dose concentration by week

published_s4 <- tibble::tibble(
  week = seq(4, 48, by = 4),
  `1.75 mg/kg IV q4w` = c(9.2, 13.7, 15.9, 17.0, 17.6, 17.9, 18.0, 18.1, 18.1, 18.1, 18.1, 18.1),
  `1.75 mg/kg IV q4w + 6 mg/kg IV load` = c(31.2, 24.4, 21.1, 19.5, 18.7, 18.4, 18.2, 18.1, 18.1, 18.1, 18.1, 18.1),
  `150 mg SC q4w` = c(9.3, 13.8, 16.0, 17.1, 17.1, 18.0, 18.2, 18.2, 18.2, 18.2, 18.2, 18.2),
  `150 mg SC q4w + weekly load` = c(51.0, 33.3, 25.5, 21.8, 20.1, 19.2, 18.8, 18.6, 18.5, 18.4, 18.3, 18.2),
  `300 mg SC q4w + weekly load` = c(101.9, 66.5, 51.0, 43.7, 40.2, 38.5, 37.6, 37.2, 37.0, 36.8, 36.6, 36.4)
) |>
  tidyr::pivot_longer(-week, names_to = "regimen", values_to = "published")

trough <- sim |>
  dplyr::filter(abs(time - (round(time / 28) * 28 - 1e-3)) < 1e-6, time > 1) |>
  dplyr::mutate(week = round(time / 7)) |>
  dplyr::group_by(regimen, week) |>
  dplyr::summarise(simulated = median(Cc), .groups = "drop")

s4 <- dplyr::inner_join(published_s4, trough, by = c("regimen", "week")) |>
  dplyr::mutate(pct_diff = 100 * (simulated - published) / published)

s4 |>
  dplyr::filter(week %in% c(4, 8, 16, 24, 48)) |>
  dplyr::rename("Regimen" = regimen, "Week" = week, "Published median Cmin (ug/mL)" = published,
                "Simulated median Cmin (ug/mL)" = simulated, "Difference (%)" = pct_diff) |>
  knitr::kable(digits = 1, caption = "Median pre-dose concentration, simulated vs Table S4 of Dumortier 2025.")
Median pre-dose concentration, simulated vs Table S4 of Dumortier 2025.
Week Regimen Published median Cmin (ug/mL) Simulated median Cmin (ug/mL) Difference (%)
4 1.75 mg/kg IV q4w 9.2 9.5 3.7
4 1.75 mg/kg IV q4w + 6 mg/kg IV load 31.2 30.8 -1.3
4 150 mg SC q4w 9.3 9.2 -1.0
4 150 mg SC q4w + weekly load 51.0 51.4 0.8
4 300 mg SC q4w + weekly load 101.9 102.4 0.5
8 1.75 mg/kg IV q4w 13.7 14.4 5.3
8 1.75 mg/kg IV q4w + 6 mg/kg IV load 24.4 24.0 -1.7
8 150 mg SC q4w 13.8 13.5 -2.2
8 150 mg SC q4w + weekly load 33.3 33.9 1.9
8 300 mg SC q4w + weekly load 66.5 67.9 2.1
16 1.75 mg/kg IV q4w 17.0 18.3 7.6
16 1.75 mg/kg IV q4w + 6 mg/kg IV load 19.5 19.5 -0.2
16 150 mg SC q4w 17.1 17.0 -0.6
16 150 mg SC q4w + weekly load 21.8 21.9 0.5
16 300 mg SC q4w + weekly load 43.7 43.4 -0.8
24 1.75 mg/kg IV q4w 17.9 19.2 7.0
24 1.75 mg/kg IV q4w + 6 mg/kg IV load 18.4 18.4 -0.1
24 150 mg SC q4w 18.0 17.9 -0.7
24 150 mg SC q4w + weekly load 19.2 19.3 0.4
24 300 mg SC q4w + weekly load 38.5 38.1 -1.0
48 1.75 mg/kg IV q4w 18.1 19.5 7.9
48 1.75 mg/kg IV q4w + 6 mg/kg IV load 18.1 17.9 -0.9
48 150 mg SC q4w 18.2 18.1 -0.6
48 150 mg SC q4w + weekly load 18.2 18.3 0.4
48 300 mg SC q4w + weekly load 36.4 36.7 0.8

stopifnot(
  abs(median(s4$pct_diff)) < 5,
  quantile(abs(s4$pct_diff), 0.9) < 15
)

Each regimen uses its own 200-subject weight sample, and the IV doses scale with weight. A single arm can therefore sit a few percent off Table S4 from sampling alone (the two IV arms reach the same steady state, but their simulated medians differ by that margin).

PKNCA validation

Steady-state Cmin, Cavg and Cmax over the last dosing interval (Weeks 48-52) are compared with Table 2. Table 2 pools the IV regimens with and without loading (steady state does not depend on loading) and pools the 150 mg SC regimens with and without loading.

ss_map <- c(
  "1.75 mg/kg IV q4w" = "1.75 mg/kg IV q4w",
  "1.75 mg/kg IV q4w + 6 mg/kg IV load" = "1.75 mg/kg IV q4w",
  "150 mg SC q4w" = "150 mg SC q4w",
  "150 mg SC q4w + weekly load" = "150 mg SC q4w",
  "300 mg SC q4w + weekly load" = "300 mg SC q4w"
)
sim_nca <- sim |>
  dplyr::filter(!is.na(Cc)) |>
  dplyr::mutate(treatment = unname(ss_map[regimen])) |>
  dplyr::select(id, time, Cc, treatment)
sim_nca <- dplyr::bind_rows(
  sim_nca,
  sim_nca |> dplyr::distinct(id, treatment) |> dplyr::mutate(time = 0, Cc = 0)
) |>
  dplyr::distinct(id, treatment, time, .keep_all = TRUE) |>
  dplyr::arrange(id, treatment, time)

dose_df <- events |>
  dplyr::filter(evid == 1) |>
  dplyr::mutate(treatment = unname(ss_map[regimen])) |>
  dplyr::select(id, time, amt, treatment)

conc_obj <- PKNCA::PKNCAconc(sim_nca, Cc ~ time | treatment + id)
dose_obj <- PKNCA::PKNCAdose(dose_df, amt ~ time | treatment + id)
intervals <- data.frame(start = 336, end = 364, cmax = TRUE, cmin = TRUE, cav = TRUE)
nca_res <- PKNCA::pk.nca(PKNCA::PKNCAdata(conc_obj, dose_obj, intervals = intervals))

Comparison against published steady-state exposure

published <- tibble::tribble(
  ~treatment, ~cmin, ~cav, ~cmax,
  "1.75 mg/kg IV q4w", 18.1, 29.2, 62.1,
  "300 mg SC q4w", 36.4, 50.1, 62.6,
  "150 mg SC q4w", 18.2, 25.1, 31.3
)
cmp <- nlmixr2lib::ncaComparisonTable(
  simulated = nca_res,
  reference = published,
  by = "treatment",
  units = c(cmin = "ug/mL", cav = "ug/mL", cmax = "ug/mL"),
  tolerance_pct = 20
)
knitr::kable(cmp, caption = "Simulated (median) vs. Table 2 (median) steady-state exposure. * differs by >20%.")
Simulated (median) vs. Table 2 (median) steady-state exposure. * differs by >20%.
NCA parameter treatment Reference Simulated % diff
Cmax (ug/mL) 1.75 mg/kg IV q4w 62.1 61.2 -1.5%
Cmax (ug/mL) 300 mg SC q4w 62.6 63.5 +1.5%
Cmax (ug/mL) 150 mg SC q4w 31.3 31.3 -0.0%
Cmin (ug/mL) 1.75 mg/kg IV q4w 18.1 18.7 +3.4%
Cmin (ug/mL) 300 mg SC q4w 36.4 36.7 +0.8%
Cmin (ug/mL) 150 mg SC q4w 18.2 18.2 -0.2%
Cavg (ug/mL) 1.75 mg/kg IV q4w 29.2 30.3 +3.7%
Cavg (ug/mL) 300 mg SC q4w 50.1 52.4 +4.6%
Cavg (ug/mL) 150 mg SC q4w 25.1 25.6 +1.9%

nca_med <- as.data.frame(nca_res) |>
  dplyr::filter(PPTESTCD %in% c("cmin", "cav", "cmax")) |>
  dplyr::group_by(treatment, PPTESTCD) |>
  dplyr::summarise(sim = median(PPORRES), .groups = "drop") |>
  dplyr::inner_join(
    tidyr::pivot_longer(published, -treatment, names_to = "PPTESTCD", values_to = "pub"),
    by = c("treatment", "PPTESTCD")
  ) |>
  dplyr::mutate(pct = 100 * (sim - pub) / pub)
stopifnot(abs(median(nca_med$pct)) < 5, max(abs(nca_med$pct)) < 15)

The simulated medians sit close to Table 2. The key result of the paper holds: 1.75 mg/kg IV q4w gives a median Cmin,ss matching 150 mg SC and a median Cmax,ss matching 300 mg SC, with Cavg,ss in between.

Terminal half-life

The Supplementary Methods report a mean terminal (beta) half-life of 28.5 days, derived from the individual CL, Vc, Q and Vp of the full analysis population (15% Asian, mean weight 81.3 kg).

hl_cohort <- data.frame(
  id = 1:200, time = 0, evid = 0, amt = 0, cmt = "central",
  WT = draw_wt(200, mean = 81.3, sd = 19.3),
  RACE_ASIAN = rbinom(200, 1, 0.15)
)
pars <- rxode2::rxSolve(mod, events = hl_cohort, returnType = "data.frame")
k10 <- pars$cl / pars$vc
k12 <- pars$q / pars$vc
k21 <- pars$q / pars$vp
beta <- 0.5 * ((k10 + k12 + k21) - sqrt((k10 + k12 + k21)^2 - 4 * k21 * k10))
thalf <- log(2) / beta
c(mean = mean(thalf), cv_pct = 100 * sd(thalf) / mean(thalf))
#>     mean   cv_pct 
#> 27.33299 26.08511
stopifnot(abs(mean(thalf) - 28.5) / 28.5 < 0.1)

Figure S2 – body weight and the 300 mg cap

wt_grid <- seq(40, 260, by = 10)
weight_events <- function(scheme, id_offset) {
  subj <- tibble::tibble(id = id_offset + seq_along(wt_grid), WT = wt_grid, RACE_ASIAN = 0L)
  doses <- tidyr::expand_grid(subj, time = dose_days)
  if (scheme == "300 mg SC q4w") {
    doses <- dplyr::mutate(doses, amt = 300, rate = 0, cmt = "depot")
    obs_t <- 336 + seq(0.5, 28, by = 0.5)
  } else {
    cap <- if (scheme == "1.75 mg/kg IV, capped at 300 mg") 300 else Inf
    doses <- dplyr::mutate(doses, amt = pmin(1.75 * WT, cap), rate = amt / tinf, cmt = "central")
    obs_t <- 336 + tinf
  }
  dplyr::bind_rows(
    dplyr::mutate(doses, evid = 1L),
    tidyr::expand_grid(subj, time = obs_t) |> dplyr::mutate(amt = 0, rate = 0, cmt = "central", evid = 0L)
  ) |>
    dplyr::mutate(scheme = scheme) |>
    dplyr::arrange(id, time, dplyr::desc(evid))
}
schemes <- c("1.75 mg/kg IV", "1.75 mg/kg IV, capped at 300 mg", "300 mg SC q4w")
wt_events <- dplyr::bind_rows(lapply(seq_along(schemes), function(i) weight_events(schemes[i], (i - 1L) * 1000L)))
wt_sim <- rxode2::rxSolve(rxode2::zeroRe(mod), events = wt_events, keep = c("scheme", "WT"),
                          returnType = "data.frame")
#> ℹ parameter labels from comments will be replaced by 'label()'
#> ℹ omega/sigma items treated as zero: 'etalcl', 'etalvc', 'etalvp'
#> Warning: multi-subject simulation without without 'omega'

wt_sim |>
  dplyr::group_by(scheme, WT) |>
  dplyr::summarise(Cmax = max(Cc), .groups = "drop") |>
  ggplot(aes(WT, Cmax, colour = scheme, linetype = scheme)) +
  geom_line() +
  labs(
    x = "Body weight (kg)", y = "Typical Cmax,ss (ug/mL)", colour = NULL, linetype = NULL,
    title = "Typical steady-state Cmax versus body weight",
    caption = "Replicates the Cmax,ss panel of Figure S2 of Dumortier 2025 (typical values)."
  ) +
  theme(legend.position = "bottom")

Figures S3, S4, S6 and S7 – exposure-response curves

conc_grid <- seq(0, 62, by = 0.5)
er_curve <- function(nm) {
  d <- data.frame(id = seq_along(conc_grid), time = 0, evid = 0, CTROUGH = conc_grid)
  s <- rxode2::rxSolve(er_ui[[nm]], d, returnType = "data.frame")
  tibble::tibble(model = nm, CTROUGH = conc_grid, p = s[[er_ui[[nm]]$predDf$var]])
}
curves <- dplyr::bind_rows(lapply(er_models$model, er_curve)) |>
  dplyr::left_join(er_models, by = "model")
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'

ggplot(curves, aes(CTROUGH, p, colour = factor(week))) +
  geom_line() +
  facet_wrap(~ paste(disease, endpoint, sep = ": "), ncol = 4) +
  labs(
    x = "Pre-dose secukinumab concentration (ug/mL)", y = "Probability of response",
    colour = "Week",
    caption = "Replicates the fitted curves of Figures S3, S4 (Week 52) and S6, S7 (Week 16) of Dumortier 2025."
  ) +
  theme(strip.text = element_text(size = 7), legend.position = "bottom")

Predicted Week 52 efficacy of the IV and SC regimens

The Results section of Dumortier 2025 reports the mean predicted response probability at Week 52, averaged over the simulated Cmin,ss distribution of each regimen. The same calculation with the packaged PK and exposure-response models:

cmin_ss <- sim |>
  dplyr::filter(abs(time - (336 - 1e-3)) < 1e-6) |>
  dplyr::mutate(treatment = unname(ss_map[regimen])) |>
  dplyr::select(id, treatment, CTROUGH = Cc)

predict_mean <- function(nm) {
  d <- dplyr::mutate(cmin_ss, time = 0, evid = 0)
  s <- rxode2::rxSolve(er_ui[[nm]], d, keep = "treatment", returnType = "data.frame")
  s$p <- s[[er_ui[[nm]]$predDf$var]]
  dplyr::summarise(dplyr::group_by(s, treatment), simulated = 100 * mean(p), .groups = "drop") |>
    dplyr::mutate(model = nm)
}

published_w52 <- tibble::tribble(
  ~disease, ~token, ~`1.75 mg/kg IV q4w`, ~`150 mg SC q4w`, ~`300 mg SC q4w`,
  "PsA", "acr20", 72, 71, 74,
  "PsA", "acr50", 46, 45, 49,
  "PsA", "acr70", 27, 27, 29,
  "PsA", "haqdi", 58, 57, 59,
  "PsA", "dactylitis", 81, 81, 76,
  "PsA", "enthesitis", 67, 67, 68,
  "PsA", "pasi90", 54, 53, 65,
  "AS", "asas20", 74, 75, 80,
  "AS", "asas40", 57, 58, 64
) |>
  tidyr::pivot_longer(-c(disease, token), names_to = "treatment", values_to = "published") |>
  dplyr::mutate(model = sprintf("Dumortier_2025_secukinumab_%s_w52_%s", tolower(disease), token))

er_cmp <- dplyr::bind_rows(lapply(unique(published_w52$model), predict_mean)) |>
  dplyr::inner_join(published_w52, by = c("model", "treatment")) |>
  dplyr::left_join(dplyr::select(er_models, model, endpoint), by = "model") |>
  dplyr::mutate(diff = simulated - published)
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'
#> Warning: multi-subject simulation without without 'omega'

er_cmp |>
  dplyr::select(disease, endpoint, treatment, published, simulated, diff) |>
  dplyr::rename("Disease" = disease, "Endpoint" = endpoint, "Regimen" = treatment,
                "Published (%)" = published, "Simulated (%)" = simulated,
                "Difference (points)" = diff) |>
  knitr::kable(digits = 1, caption = "Mean predicted Week 52 response, simulated vs. Dumortier 2025 Results.")
Mean predicted Week 52 response, simulated vs. Dumortier 2025 Results.
Disease Endpoint Regimen Published (%) Simulated (%) Difference (points)
PsA ACR20 1.75 mg/kg IV q4w 72 71.4 -0.6
PsA ACR20 150 mg SC q4w 71 71.4 0.4
PsA ACR20 300 mg SC q4w 74 73.5 -0.5
PsA ACR50 1.75 mg/kg IV q4w 46 45.9 -0.1
PsA ACR50 150 mg SC q4w 45 46.0 1.0
PsA ACR50 300 mg SC q4w 49 49.4 0.4
PsA ACR70 1.75 mg/kg IV q4w 27 27.4 0.4
PsA ACR70 150 mg SC q4w 27 27.5 0.5
PsA ACR70 300 mg SC q4w 29 29.3 0.3
PsA HAQ-DI response 1.75 mg/kg IV q4w 58 57.8 -0.2
PsA HAQ-DI response 150 mg SC q4w 57 57.8 0.8
PsA HAQ-DI response 300 mg SC q4w 59 59.6 0.6
PsA Resolution of dactylitis 1.75 mg/kg IV q4w 81 80.9 -0.1
PsA Resolution of dactylitis 150 mg SC q4w 81 80.7 -0.3
PsA Resolution of dactylitis 300 mg SC q4w 76 76.3 0.3
PsA Resolution of enthesitis 1.75 mg/kg IV q4w 67 67.6 0.6
PsA Resolution of enthesitis 150 mg SC q4w 67 67.6 0.6
PsA Resolution of enthesitis 300 mg SC q4w 68 68.2 0.2
PsA PASI90 1.75 mg/kg IV q4w 54 54.3 0.3
PsA PASI90 150 mg SC q4w 53 54.3 1.3
PsA PASI90 300 mg SC q4w 65 65.9 0.9
AS ASAS20 1.75 mg/kg IV q4w 74 74.8 0.8
AS ASAS20 150 mg SC q4w 75 74.9 -0.1
AS ASAS20 300 mg SC q4w 80 80.5 0.5
AS ASAS40 1.75 mg/kg IV q4w 57 57.6 0.6
AS ASAS40 150 mg SC q4w 58 57.6 -0.4
AS ASAS40 300 mg SC q4w 64 63.6 -0.4

stopifnot(
  abs(median(er_cmp$diff)) < 2,
  quantile(abs(er_cmp$diff), 0.9) < 4
)

Assumptions and deviations

  • Exposure-response parameters are figure-derived. No E0, Emax or EC50 is printed anywhere in the paper or supplement. All 96 values were digitised by the maintainers from the fitted curves of Figures S3, S4, S6 and S7 and refitted with the published equation (Hill fixed at 2, as the paper states). The refit RMSE per panel is in each model’s description. Three Week 52 PsA curves are only partly identified by the plotted range:
    • ACR70 and resolution of enthesitis: the curve is already near zero at the left edge of the plot, so E0 is only bounded from above; the least-squares optimum is reported.
    • Resolution of dactylitis: the curve decreases with exposure and the plot shows only the start of the sigmoid, so EC50 and Emax are not separately identifiable. EC50 was set to 400 ug/mL, on the ridge of equally good fits (the limiting form over 0-62 ug/mL is logit(p) = 1.529 - 1.785e-4 * Cmin^2). Do not extrapolate any of these three models beyond 0-62 ug/mL.
  • Figure S3 HAQ-DI panel. Its y-axis labels read 0.0, 0.3, 0.4, 0.6 on equally spaced ticks; the “0.3” is a misprint for 0.2 (equal tick spacing of a linear axis) and the axis was calibrated as 0, 0.2, 0.4, 0.6.
  • Endpoint definitions. Supplementary Table S2 lists “ASDAS-CRP major improvement” twice; the second row (“ASDAS-CRP score <= 1.3”) is ASDAS-CRP inactive disease, as the figure panels show. Table S2 defines PASDAS LDA as a score between 1.9 and 3.2, whereas the figure panels are titled “PASDAS LDA including remission”; the packaged output follows the figures.
  • CTROUGH input. The exposure-response models take the pre-dose concentration at the assessment visit as a covariate. At Week 52 this is Cmin,ss; at Week 16 it is the Week 16 pre-dose concentration (0 for placebo patients). The models do not compute exposure themselves.
  • Placeholder residual. Each exposure-response model carries a fixed additive residual SD of 0.001 on the probability so nlmixr2 accepts the model; the source fits used a Bernoulli likelihood with no residual.
  • Fixed-to-zero random effects omitted. The control stream declares ETA(3) (Q), ETA(5) (KA) and ETA(6) (logit F1) with variance 0 FIX, and an additive residual 0 FIX. They have no effect and are not carried. KA is fixed at 0.18/day as in the control stream and Table S3 (the Supplementary Methods text quotes 0.1801/day, the value estimated in psoriasis by Bruin 2017).
  • Weight effect on Q. The main text lists a weight effect on the intercompartmental flow, but neither the control stream nor Table S3 has one; Q is unscaled as in the control stream.
  • Final vs initial estimates. The $THETA/$OMEGA/$SIGMA values in the supplementary control stream are initial estimates (e.g. CL 0.181); the packaged values are the final estimates of Table S3.
  • Simulation design. Infusion duration (30 minutes) and the body-weight distribution of the simulated INVIGORATE patients are not stated in the paper; a 30-minute infusion and a log-normal weight with mean 79 kg and SD 19 kg were used. Cohorts use 200 subjects per regimen instead of the paper’s 6000.
  • Exposure-safety models not packaged. The Cox models with a penalised spline of the running-average concentration have a non-parametric baseline hazard and unreported spline coefficients.
  • No erratum or correction notice was found for this article (Europe PMC, checked 2026-11-05).